A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway
This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398,
administered on a continuous once and/or twice daily schedule.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence rate and category of dose limiting toxicities (DLTs)
Maximum tolerated dose (MTD) and/or Recommended dose (RD) of single agent oral BGJ398
First cycle of 28 days
Japan: Ministry of Health, Labor and Welfare